MA26451A1 - Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant. - Google Patents

Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.

Info

Publication number: MA26451A1
Authority: MA; Morocco
Prior art keywords: apo; amides; preparation; pharmaceutical compositions; compositions containing
Prior art date: 1996-11-27

Application number

MA24877A

Other languages

English (en)

Inventor

Chang George

Joseph Quallich George

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-11-27

Filing date

1997-11-26

Publication date

2004-12-20

1997-11-26 Application filed by Pfizer filed Critical Pfizer

2004-12-20 Publication of MA26451A1 publication Critical patent/MA26451A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

MA24877A 1996-11-27 1997-11-26 Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant. MA26451A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US3230796P	1996-11-27	1996-11-27

Publications (1)

Publication Number	Publication Date
MA26451A1 true MA26451A1 (fr)	2004-12-20

Family

ID=21864233

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA24877A MA26451A1 (fr)	1996-11-27	1997-11-26	Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.

Country Status (34)

Country	Link
US (1)	US6121283A (fr)
EP (1)	EP0944602A1 (fr)
JP (1)	JP3270764B2 (fr)
KR (1)	KR100334567B1 (fr)
CN (2)	CN1238764A (fr)
AP (1)	AP804A (fr)
AR (1)	AR010309A1 (fr)
AU (1)	AU716151B2 (fr)
BG (2)	BG103434A (fr)
BR (1)	BR9714364A (fr)
CA (1)	CA2272719C (fr)
CZ (1)	CZ292160B6 (fr)
DZ (1)	DZ2358A1 (fr)
EA (1)	EA001539B1 (fr)
GT (1)	GT199700122A (fr)
HN (1)	HN1997000144A (fr)
HR (1)	HRP970642A2 (fr)
ID (1)	ID18995A (fr)
IL (1)	IL129744A0 (fr)
IS (1)	IS5040A (fr)
MA (1)	MA26451A1 (fr)
NO (1)	NO312760B1 (fr)
NZ (1)	NZ335162A (fr)
OA (1)	OA11050A (fr)
PA (1)	PA8441601A1 (fr)
PE (1)	PE17199A1 (fr)
SK (1)	SK65499A3 (fr)
TN (1)	TNSN97193A1 (fr)
TR (1)	TR199901180T2 (fr)
TW (1)	TW502023B (fr)
UY (1)	UY24789A1 (fr)
WO (1)	WO1998023593A1 (fr)
YU (1)	YU23499A (fr)
ZA (1)	ZA9710641B (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en)	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
MX9709914A (es) *	1995-06-07	1998-03-31	Pfizer	Derivados de acido bifenil-2-carboxilico-tetrahidro-isoquinolin-6-ilo, su preparacion y el uso de los mismos.
GB9708805D0 (en)	1997-05-01	1997-06-25	Smithkline Beecham Plc	Compounds
US5968950A (en) *	1997-06-23	1999-10-19	Pfizer Inc	Apo B-secretion/MTP inhibitor hydrochloride salt
GB9810876D0 (en)	1998-05-20	1998-07-22	Smithkline Beecham Plc	Compounds
AU4543899A (en)	1998-06-08	1999-12-30	Advanced Medicine, Inc.	Multibinding inhibitors of microsomal triglyceride transferase protein
PL347237A1 (en)	1998-10-08	2002-03-25	Smithkline Beecham Plc	Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
GB9826412D0 (en)	1998-12-03	1999-01-27	Glaxo Group Ltd	Chemical compounds
EP1354604A1 (fr) *	1998-12-23	2003-10-22	G.D. Searle LLC.	Combinaisons pour indications cardiovasculaires
DE69908643T2 (de)	1998-12-23	2004-05-13	G.D. Searle Llc, Chicago	Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
EA005815B1 (ru) *	1998-12-23	2005-06-30	Джи.Ди.Сирл Ллс	Комбинация ингибиторов транспорта желчных кислот в подвздошной кишке и ингибиторов белка, переносящего эфиры холестерина, для сердечно-сосудистых показаний
DE19929012A1 (de) *	1999-06-25	2000-12-28	Bayer Ag	Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln
DE19929031A1 (de) *	1999-06-25	2000-12-28	Bayer Ag	Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln
DE19929065A1 (de) *	1999-06-25	2000-12-28	Bayer Ag	Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
WO2001005767A1 (fr) *	1999-07-20	2001-01-25	Novartis Ag	Composes organiques
CA2324800A1 (fr) *	1999-11-10	2001-05-10	Mary Anne Hickman	Utilisation d'inhibiteurs de secretion d'apo b et/ou de mtp
IL139450A0 (en) *	1999-11-10	2001-11-25	Pfizer Prod Inc	Methods of administering apo b-secretion/mtp inhibitors
CA2324801A1 (fr) *	1999-11-10	2001-05-10	Andrew Gordon Swick	Utilisation d'inhibiteurs de secretion d'apo b et/ou de mtp et d'agents contre l'obesite
CO5271688A1 (es) *	1999-11-10	2003-04-30	Pfizer Prod Inc	Uso de inhibidor de secrecion de apoliproteinas b y/o de proteina de transferencia de trigliceridos microsmales
ATE295836T1 (de) *	2000-01-18	2005-06-15	Novartis Pharma Gmbh	Carboxamide und ihre verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und der apolipoprotein b (apo b) sekretion
ATE286500T1 (de) *	2000-03-14	2005-01-15	Actelion Pharmaceuticals Ltd	1,2,3,4-tetrahydroisochinolin-derivate
AU2001262185A1 (en) *	2000-04-10	2001-10-23	Novartis Ag	Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0013383D0 (en) *	2000-06-01	2000-07-26	Glaxo Group Ltd	Therapeutic benzamide derivatives
GB0013346D0 (en) *	2000-06-01	2000-07-26	Glaxo Group Ltd	Therapeutic benzamide derivatives
WO2002014277A1 (fr) *	2000-08-10	2002-02-21	Tanabe Seiyaku Co., Ltd.	Composes de biphenylcarboxamidoisoindoline, procedes de preparation de ceux-ci et produits intermediaires destines a la synthese de ceux-ci
AU2001277727A1 (en) *	2000-08-10	2002-02-25	Tanabe Seiyaku Co., Ltd.	Benzoylaminoisoindoline compounds, processes for the preparation of the same andintermediates for the synthesis thereof
PL362244A1 (en) *	2000-09-01	2004-10-18	Sankyo Company, Limited	Medicinal compositions
JO2654B1 (en)	2000-09-04	2012-06-17	شركة جانسين فارماسوتيكا ان. في	Multiple aryl caroxa amides are useful as lipid - lowering agents
CA2425097A1 (fr) *	2000-10-05	2002-04-11	Fujisawa Pharmaceutical Co., Ltd.	Composes a base de benzamide, inhibiteurs des secretions d'apolipoproteine b
JO2409B1 (en)	2000-11-21	2007-06-17	شركة جانسين فارماسوتيكا ان. في	Second-phenyl carboxy amides are useful as lipid-lowering agents
WO2002090347A1 (fr) *	2001-04-30	2002-11-14	Fujisawa Pharmaceutical Co., Ltd.	Composes biarylcarboxamide comme inhibiteurs d'apolipoproteine b
CA2450957A1 (fr) *	2001-06-22	2003-01-03	Pfizer Products Inc.	Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres
HU229551B1 (hu) *	2001-06-28	2014-01-28	Zoetis P Llc	Mikroszóma triglicerid transzfer protein (MTP) és/vagy apolipoprotein B(APO B) kiválasztás inhibitorokként alkalmazható triamiddal helyettesített indol-, benzofurán- és benzotiofén-származékok
US20030144350A1 (en) *	2001-07-20	2003-07-31	Adipogenix, Inc.	Fat accumulation-modulation compounds
WO2003013516A1 (fr) *	2001-08-10	2003-02-20	Adipogenix, Inc.	Composes servant a moduler l'accumulation des graisses
JP2005510564A (ja) *	2001-11-28	2005-04-21	藤沢薬品工業株式会社	アポリポタンパク質ｂ阻害剤としての複素環式アミド化合物
JP2005521653A (ja)	2002-01-17	2005-07-21	ファルマシアコーポレイション	先端ナトリウム同時依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取込みの阻害剤としての新規アルキル／アリールヒドロキシまたはケトチエピン化合物
EP1469833B1 (fr)	2002-02-01	2021-05-19	Bend Research, Inc.	Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen d'un appareil de sechage par pulverisation modifie
NZ531890A (en) *	2002-02-28	2006-02-24	Japan Tobacco Inc	Ester compound and medicinal use thereof
NZ535366A (en) *	2002-03-13	2007-07-27	Univ Tennessee Res Foundation	Substituted tetrahydroisoquinoline compounds, methods of making, and their use
WO2004039795A2 (fr) *	2002-10-29	2004-05-13	Fujisawa Pharmaceutical Co., Ltd.	Composes amide
MXPA05006679A (es) *	2002-12-20	2005-08-16	Pfizer Prod Inc	Inhibidores de la proteina de transferencia de trigliceridos microsomales.
JP2006514032A (ja) *	2002-12-20	2006-04-27	ファイザー・プロダクツ・インク	ミクロソームトリグリセリド転送タンパク質阻害剤
US7276536B2 (en)	2003-03-17	2007-10-02	Japan Tobacco Inc.	Method for increasing the bioavailability of the active form of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino) phenyl] 2-methylpropanethioate
JP4832897B2 (ja)	2003-08-29	2011-12-07	日本たばこ産業株式会社	エステル誘導体及びその医薬用途
RU2378257C2 (ru)	2004-03-01	2010-01-10	Актелион Фармасьютиклз Лтд	Замещенные производные 1,2,3,4-тетрагидроизохинолина
CA2910191C (fr)	2004-03-05	2022-03-08	The Trustees Of The Univeristy Of Pennsylvania	L'utilisation d'inhibiteurs mtp pour le traitement a faibles effets secondaires contre des affections liees a l'hyperlipidemie et l'hypercholesterolemie
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030623A1 (en) *	2004-07-16	2006-02-09	Noboru Furukawa	Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
US8101774B2 (en)	2004-10-18	2012-01-24	Japan Tobacco Inc.	Ester derivatives and medicinal use thereof
AU2005297923B2 (en) *	2004-10-25	2010-12-23	Japan Tobacco Inc.	Solid medicinal preparation improved in solubility and stability and process for producing the same
WO2006050999A2 (fr) *	2004-11-15	2006-05-18	Obe Therapy Biotechnology S.A.S	Compositions pharmaceutiques et procedes de reduction de la graisse corporelle
CA2590533C (fr)	2004-11-23	2010-09-07	Warner-Lambert Company Llc	Derives d'acide 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoique comme inhibiteurs de hmg co-a reductase pour le traitement de l'hyperlipidemie
JP2006249022A (ja)	2005-03-11	2006-09-21	Sumitomo Chemical Co Ltd	４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法
CA2605510C (fr)	2005-04-19	2013-12-24	Surface Logix, Inc.	Inhibiteurs des secretions microsomales des apo-b et des proteines de transfert des triglycerides
JP2008542255A (ja) *	2005-05-27	2008-11-27	ファイザー・プロダクツ・インク	肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
US7741317B2 (en)	2005-10-21	2010-06-22	Bristol-Myers Squibb Company	LXR modulators
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
US8383660B2 (en)	2006-03-10	2013-02-26	Pfizer Inc.	Dibenzyl amine compounds and derivatives
KR20080109841A (ko) *	2006-03-10	2008-12-17	뉴로젠 코포레이션	피페라지닐 옥소알킬 테트라히드로이소퀴놀린 및 관련유사체
US7919506B2 (en)	2006-03-10	2011-04-05	Pfizer Inc.	Dibenzyl amine compounds and derivatives
SG10201406016SA (en) *	2006-04-03	2014-11-27	Stella Aps	Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
CA3024953A1 (fr)	2006-04-03	2007-10-11	Roche Innovation Center Copenhagen A/S	Composition pharmaceutique comprenant des oligonucleotides antisens anti-microarn
US20090042835A1 (en) *	2006-06-02	2009-02-12	Davis Roger A	Compositions and methods for ameliorating hyperlipidemia
AU2007254827A1 (en) *	2006-06-02	2007-12-13	San Diego State University Research Foundation	Compositions and methods for ameliorating hyperlipidemia
AU2007306361A1 (en) *	2006-10-09	2008-04-17	Santaris Pharma A/S	RNA antagonist compounds for the modulation of PCSK9
CL2007002958A1 (es) *	2006-10-12	2008-05-09	Epix Delaware Inc	Compuestos derivados de heteroaril-carboxamida, antagonistas del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades tales como rechazo de transplante de organos, artritis reumatoidea, lupus, entr
JO2653B1 (en)	2006-10-24	2012-06-17	شركة جانسين فارماسوتيكا ان. في	Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
ATE469122T1 (de) *	2006-10-24	2010-06-15	Janssen Pharmaceutica Nv	Mtp-inhibierende tetrahydronaphthalin-1- carbonsäurederivate
ATE547394T1 (de)	2006-12-01	2012-03-15	Bristol Myers Squibb Co	N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
WO2008075949A1 (fr) *	2006-12-20	2008-06-26	Friesland Brands B.V.	Modulation de l'expression génique d'une protéine microsomale de transfert des triglycérides (mtp ou mttp) au moyen de microorganismes alimentaires ingérés/de qualité alimentaire
WO2008079398A1 (fr) *	2006-12-21	2008-07-03	Aegerion Pharmaceuticals, Inc.	Procédés de traitement de l'obésité à l'aide d'une combinaison comprenant un inhibiteur de mtp et un inhibiteur de l'absorption du cholestérol
WO2008113832A2 (fr) *	2007-03-22	2008-09-25	Santaris Pharma A/S	Composés arn antagonistes courts pour la modulation de l'arnm cible
CA2681406A1 (fr) *	2007-03-22	2008-09-25	Santaris Pharma A/S	Composes arn antagonistes pour l'inhibition de l'expression de l'apo-b100
KR20100040872A (ko) *	2007-06-25	2010-04-21	뉴로젠 코포레이션	피페라지닐 옥소알킬 테트라하이드로-베타-카르볼린 및 이의 관련 유사체
WO2009027527A2 (fr) *	2007-08-30	2009-03-05	Santaris Pharma A/S	Composes antagonistes d'arn permettant la modulation de fabp4/ap2
CA2701547C (fr) *	2007-10-04	2020-03-10	Santaris Pharma A/S	Oligonucleotiques qui ciblent et inhibent les micro arn
ES2575131T3 (es)	2007-12-03	2016-06-24	Obe Therapy Biotechnology	Inhibidores boropéptidos de enteropeptidasa y sus usos en tratamientos de obesidad, sobrepeso y/o enfermedades asociadas con un metabolismo anormal de la grasa
JP2011506466A (ja)	2007-12-11	2011-03-03	株式会社サイトパスファインダー	カルボキサミド化合物ならびにケモカイン受容体アゴニストとしてのそれらの使用
US20090197947A1 (en) *	2008-02-01	2009-08-06	The Research Foundation Of State University Of New York	Medicaments and methods for lowering plasma lipid levels and screening drugs
EP2268811A1 (fr) *	2008-03-07	2011-01-05	Santaris Pharma A/S	Compositions pharmaceutiques pour le traitement de maladies associées aux microarn
ES2541442T3 (es)	2008-08-01	2015-07-20	Roche Innovation Center Copenhagen A/S	Modulación mediada por microARN de factores estimulantes de colonias
US9034837B2 (en) *	2009-04-24	2015-05-19	Roche Innovation Center Copenhagen A/S	Pharmaceutical compositions for treatment of HCV patients that are poor-responders to interferon
US8563528B2 (en)	2009-07-21	2013-10-22	Santaris Pharma A/S	Antisense oligomers targeting PCSK9
CA2909442A1 (fr)	2013-04-17	2014-10-23	Pfizer Inc.	Derives de n-piperidin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
SG11201510656PA (en)	2013-06-27	2016-01-28	Roche Innovation Ct Copenhagen As	Antisense oligomers and conjugates targeting pcsk9
WO2015065595A1 (fr)	2013-10-30	2015-05-07	Trustees Of Dartmouth College	Procédé d'inhibition sélective d'acat1 dans le traitement de l'obésité, du syndrome métabolique et de l'athérosclérose
WO2016055901A1 (fr)	2014-10-08	2016-04-14	Pfizer Inc.	Composés d'amide substitué
JP2018502900A (ja) *	2014-10-22	2018-02-01	ザボードオブリージェンツオブザユニバーシティーオブテキサスシステム	ジスコイジンドメイン受容体１を標的化する小分子阻害剤およびその使用
HUE069590T2 (hu)	2019-01-18	2025-03-28	Astrazeneca Ab	PCSK9-gátló 6'-[[(1s,3s)-3-[[5-(difluormetoxi)-2-pirimidinil]amino]ciklopentil]amino][1(2h ),3'-bipiridin]-2-on és alkalmazására szolgáló eljárások
AU2021316011A1 (en)	2020-07-29	2023-02-09	Amryt Pharmaceuticals Inc.	Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients
BR112023019288A2 (pt) *	2021-03-26	2023-10-24	Chiesi Farm Spa	Derivados de indolina como inibidores de ddrs
JP2024513180A (ja) *	2021-03-26	2024-03-22	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	Ｄｄｒ阻害物質としてのインドリン誘導体
CN113292493A (zh) *	2021-06-23	2021-08-24	上海立科化学科技有限公司	5,7-二氯-1,2,3,4-四氢异喹啉的制备方法
WO2024216197A2 (fr) *	2023-04-13	2024-10-17	Acelot, Inc.	Composés et méthodes de traitement de maladies à agrégation de protéines
US12453728B1 (en)	2024-08-08	2025-10-28	Redux Therapeutics, Llc	Compositions comprising inhibitors of microsomal triglyceride transfer protein and Apo-B secretion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4022900A (en) *	1970-09-09	1977-05-10	Marion Laboratories, Inc.	Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
US5595872A (en) *	1992-03-06	1997-01-21	Bristol-Myers Squibb Company	Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) *	1993-09-03	1998-04-14	Bristol-Myers Squibb Company	Inhibitors of microsomal triglyceride transfer protein and method
WO1996040640A1 (fr) *	1995-06-07	1996-12-19	Pfizer Inc.	DERIVES DE BIPHENYL-2-ACIDE CARBOXYLIQUE-TETRAHYDRO-ISOQUINOLEINE-6-YL AMIDES, PREPARATION DE CES AMIDES ET UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE TRIGLYCERIDE MICROSOMAL ET/OU DE LA SECRETION D'APOLIPOPROTEINES B (Apo B)

1997
- 1997-11-03 EP EP97945048A patent/EP0944602A1/fr not_active Withdrawn
- 1997-11-03 BR BR9714364A patent/BR9714364A/pt not_active Application Discontinuation
- 1997-11-03 EA EA199900416A patent/EA001539B1/ru not_active IP Right Cessation
- 1997-11-03 JP JP52446498A patent/JP3270764B2/ja not_active Expired - Fee Related
- 1997-11-03 WO PCT/IB1997/001368 patent/WO1998023593A1/fr not_active Ceased
- 1997-11-03 SK SK654-99A patent/SK65499A3/sk unknown
- 1997-11-03 US US09/284,466 patent/US6121283A/en not_active Expired - Fee Related
- 1997-11-03 AU AU46347/97A patent/AU716151B2/en not_active Ceased
- 1997-11-03 NZ NZ335162A patent/NZ335162A/xx unknown
- 1997-11-03 TR TR1999/01180T patent/TR199901180T2/xx unknown
- 1997-11-03 KR KR1019997004662A patent/KR100334567B1/ko not_active Expired - Fee Related
- 1997-11-03 CA CA002272719A patent/CA2272719C/fr not_active Expired - Fee Related
- 1997-11-03 CN CN97180033A patent/CN1238764A/zh active Pending
- 1997-11-03 YU YU23499A patent/YU23499A/sh unknown
- 1997-11-03 IL IL12974497A patent/IL129744A0/xx unknown
- 1997-11-04 HN HN1997000144A patent/HN1997000144A/es unknown
- 1997-11-05 TW TW086116476A patent/TW502023B/zh not_active IP Right Cessation
- 1997-11-14 PA PA84416A patent/PA8441601A1/es unknown
- 1997-11-20 AP APAP/P/1997/001145A patent/AP804A/en active
- 1997-11-24 PE PE1997001062A patent/PE17199A1/es not_active Application Discontinuation
- 1997-11-25 UY UY24789A patent/UY24789A1/es not_active Application Discontinuation
- 1997-11-25 GT GT199700122A patent/GT199700122A/es unknown
- 1997-11-25 ID IDP973763A patent/ID18995A/id unknown
- 1997-11-26 DZ DZ970208A patent/DZ2358A1/fr active
- 1997-11-26 TN TNTNSN97193A patent/TNSN97193A1/fr unknown
- 1997-11-26 MA MA24877A patent/MA26451A1/fr unknown
- 1997-11-26 AR ARP970105560A patent/AR010309A1/es unknown
- 1997-11-26 ZA ZA9710641A patent/ZA9710641B/xx unknown
- 1997-11-26 HR HR60/032,307A patent/HRP970642A2/hr not_active Application Discontinuation
1999
- 1999-04-30 IS IS5040A patent/IS5040A/is unknown
- 1999-05-19 OA OA9900106A patent/OA11050A/en unknown
- 1999-05-26 BG BG103434A patent/BG103434A/xx unknown
- 1999-05-26 BG BG108830A patent/BG108830A/bg unknown
- 1999-05-26 NO NO19992525A patent/NO312760B1/no unknown
2002
- 2002-02-19 CN CN02105189A patent/CN1380289A/zh active Pending
- 2002-09-17 CZ CZ20023137A patent/CZ292160B6/cs not_active IP Right Cessation

Also Published As

Publication number	Publication date
YU23499A (sh)	2001-07-10
UY24789A1 (es)	2000-09-29
AU716151B2 (en)	2000-02-17
SK65499A3 (en)	2001-05-10
NO992525L (no)	1999-05-26
KR20000057269A (ko)	2000-09-15
TNSN97193A1 (fr)	2005-03-15
NO312760B1 (no)	2002-07-01
WO1998023593A1 (fr)	1998-06-04
AU4634797A (en)	1998-06-22
PE17199A1 (es)	1999-02-19
AR010309A1 (es)	2000-06-07
BR9714364A (pt)	2000-03-21
JP3270764B2 (ja)	2002-04-02
HN1997000144A (es)	1997-12-16
TW502023B (en)	2002-09-11
US6121283A (en)	2000-09-19
AP804A (en)	2000-01-28
NZ335162A (en)	2000-01-28
NO992525D0 (no)	1999-05-26
PA8441601A1 (es)	2000-05-24
AP9701145A0 (en)	1998-01-31
BG103434A (en)	2000-07-31
CN1380289A (zh)	2002-11-20
BG108830A (bg)	2005-10-31
CA2272719C (fr)	2002-10-01
IL129744A0 (en)	2000-02-29
EP0944602A1 (fr)	1999-09-29
ID18995A (id)	1998-05-28
JP2000505810A (ja)	2000-05-16
KR100334567B1 (ko)	2002-05-03
EA001539B1 (ru)	2001-04-23
ZA9710641B (en)	1999-05-26
EA199900416A1 (ru)	1999-12-29
OA11050A (en)	2002-03-07
IS5040A (is)	1999-04-30
TR199901180T2 (xx)	1999-08-23
HRP970642A2 (en)	1998-10-31
GT199700122A (es)	1999-05-19
CA2272719A1 (fr)	1998-06-04
CN1238764A (zh)	1999-12-15
CZ292160B6 (cs)	2003-08-13
DZ2358A1 (fr)	2002-12-28

Publication	Publication Date	Title
MA26451A1 (fr)	2004-12-20	Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26687A1 (fr)	2004-12-20	4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2780057B1 (fr)	2002-09-13	Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26630A1 (fr)	2004-12-20	4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26494A1 (fr)	2004-12-20	Inhibiteurs de proteases nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2748026B1 (fr)	1998-06-05	Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA26424A1 (fr)	2004-12-20	Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26415A1 (fr)	2004-12-20	Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
MA23866A1 (fr)	1996-12-31	N-(indole-2-carbonyl)-glycinamides substitues, procede pour leur preparation et compositions les contenant
MA26508A1 (fr)	2004-12-20	Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation.
MA26559A1 (fr)	2004-12-20	Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
FR2729951B1 (fr)	1997-04-18	Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
MA26432A1 (fr)	2004-12-20	Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26433A1 (fr)	2004-12-20	Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26622A1 (fr)	2004-12-20	Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26443A1 (fr)	2004-12-20	Aralkyl- et aralkylidene-lactames et -imides heterocycliques, procedes pour leur preparation et compositions pharmaceutiques les contenant
MA26439A1 (fr)	2004-12-20	Derives d'indazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA24529A1 (fr)	1998-12-31	Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions les contenant .
FR2740136B1 (fr)	1998-01-09	Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2751334B1 (fr)	1998-10-16	Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26425A1 (fr)	2004-12-20	Derives de lactames, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2665453B1 (fr)	1995-01-27	Polylactides purifies, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26499A1 (fr)	2004-12-20	Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
MA26558A1 (fr)	2004-12-20	Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26487A1 (fr)	2004-12-20	Heterocyclecetohydrazides inhibiteurs de proteases, procede pour leur preparation et compositions pharmaceutiques les contenant .